Spine Bone Texture Assessed by Trabecular Bone Score (TBS) to Evaluate Bone Health in Thalassemia Major.

Détails

ID Serval
serval:BIB_7CC71B8BCFAF
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Spine Bone Texture Assessed by Trabecular Bone Score (TBS) to Evaluate Bone Health in Thalassemia Major.
Périodique
Calcified Tissue International
Auteur⸱e⸱s
Baldini M., Ulivieri F.M., Forti S., Serafino S., Seghezzi S., Marcon A., Giarda F., Messina C., Cassinerio E., Aubry-Rozier B., Hans D., Cappellini M.D.
ISSN
1432-0827 (Electronic)
ISSN-L
0171-967X
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
95
Numéro
6
Pages
540-546
Langue
anglais
Notes
Publication types: Journal Article
Résumé
Due to the increasing survival of thalassemic patients, osteopathy is a mounting clinical problem. Low bone mass alone cannot account for the high fracture risk described; impaired bone quality has been speculated but so far it cannot be demonstrated noninvasively. We studied bone quality in thalassemia major using trabecular bone score (TBS), a novel texture measurement extracted from spine dual-energy X-ray absorptiometry (DXA), proposed in postmenopausal and secondary osteoporosis as an indirect index of microarchitecture. TBS was evaluated in 124 adult thalassemics (age range 19-56 years), followed-up with optimal transfusional and therapeutical regimens, and in 65 non-thalassemic patients (22-52 years) undergoing DXA for different bone diseases. TBS was lower in thalassemic patients (1.04 ± 0.12 [range 0.80-1.30]) versus controls (1.34 ± 0.11 [1.06-1.52]) (p < 0.001), and correlated with BMD. TBS and BMD values correlated with age, indicating that thalassemia negatively affects both bone quality and quantity, especially as the patient gets older. TBS was 1.02 ± 0.11 [0.80-1.28] in the osteoporotic thalassemic patients, 1.08 ± 0.12 [0.82-1.30] in the osteopenic ones and 1.15 ± 0.10 [0.96-1.26] in those with normal BMD. No gender differences were found (males: 1.02 ± 0.13 [0.80-1.30], females 1.05 ± 0.11 [0.80-1.30]), nor between patients with and without endocrine-metabolic disorders affecting bone metabolism. Our findings from a large population with thalassemia major show that TBS is a valuable tool to assess noninvasively bone quality, and it may be related to fragility fracture risk in thalassemic osteopathy.
Pubmed
Web of science
Création de la notice
27/12/2014 9:21
Dernière modification de la notice
20/08/2019 14:38
Données d'usage